# Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults

> **NCT00995540** · PHASE2 · TERMINATED · sponsor: **Exsulin Corporation** · enrollment: 23 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** INGAP Peptide
- **DRUG:** INGAP Peptide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00995540
- **Lead sponsor:** Exsulin Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Preserve clinical supplies
- **Last updated:** 2014-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00995540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00995540, "Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00995540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*